Impact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials

dc.creatorSahebkar A.
dc.creatorSimental-Mendía L.E.
dc.creatorPirro M.
dc.creatorMontecucco F.
dc.creatorCarbone F.
dc.creatorBanach M.
dc.creatorBarreto G.E.
dc.creatorButler A.E.
dc.date.accessioned2020-09-02T22:27:37Z
dc.date.accessioned2022-11-08T20:23:13Z
dc.date.available2020-09-02T22:27:37Z
dc.date.available2022-11-08T20:23:13Z
dc.date.created2020-09-02T22:27:37Z
dc.date.issued2018
dc.identifier50, 6, 485-493
dc.identifier07853890
dc.identifierhttps://hdl.handle.net/20.500.12728/6136
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5144748
dc.languageen
dc.publisherTaylor and Francis Ltd
dc.subjectcystatin C
dc.subjectfenofibrate
dc.subjectFibrates
dc.subjectcystatin C
dc.subjectfenofibrate
dc.subjectfibric acid derivative
dc.subjectantilipemic agent
dc.subjectcystatin C
dc.subjectfibric acid derivative
dc.subjectlow density lipoprotein cholesterol
dc.subjectperoxisome proliferator activated receptor alpha
dc.subjectPPARA protein, human
dc.subjectcardiovascular risk
dc.subjectdrug efficacy
dc.subjectdyslipidemia
dc.subjecthuman
dc.subjectmeta analysis
dc.subjectpriority journal
dc.subjectprotein blood level
dc.subjectrandomized controlled trial (topic)
dc.subjectReview
dc.subjectrisk reduction
dc.subjectsystematic review
dc.subjectblood
dc.subjectcardiovascular disease
dc.subjectclinical trial (topic)
dc.subjecthypertriglyceridemia
dc.subjectmetabolism
dc.subjectpathology
dc.subjecttreatment outcome
dc.subjectCardiovascular Diseases
dc.subjectCholesterol, LDL
dc.subjectClinical Trials as Topic
dc.subjectCystatin C
dc.subjectFibric Acids
dc.subjectHumans
dc.subjectHypertriglyceridemia
dc.subjectHypolipidemic Agents
dc.subjectPPAR alpha
dc.subjectTreatment Outcome
dc.titleImpact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials
dc.typeReview


Este ítem pertenece a la siguiente institución